The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
Abstract
Summary We consider the case of phase I trials for treatment of cancer or other severe diseases in which grade information is available about the severity of toxicity. Most dose allocation procedures dichotomize toxicity grades based on being dose limiting, which may not work well for severe and possibly irreversible toxicities such as renal, liver, and neurological toxicities, or toxicities with long duration. We propose a simple extension to the continual reassessment method (CRM), called the Quasi‐CRM, to incorporate grade information. Toxicity grades are first converted to numeric scores that reflect their impacts on the dose allocation procedure, and then incorporated into the CRM using the quasi‐Bernoulli likelihood. A simulation study demonstrates that the Quasi‐CRM is superior to the standard CRM and comparable to a univariate version of the Bekele and Thall method (2004, Journal of the American Statistical Association99, 26–35). We also present sensitivity analysis of the new method with respect to toxicity scores, and discuss practical issues such as extending the simple algorithmic up‐and‐down designs.
Citing Literature
Number of times cited according to CrossRef: 67
- Márcio A. Diniz, Sungjin Kim, Mourad Tighiouart, A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades, Stats, 10.3390/stats3030017, 3, 3, (221-238), (2020).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Model-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_3, (33-79), (2019).
- Moreno Ursino, Ying Yuan, Corinne Alberti, Emmanuelle Comets, Geraldine Favrais, Tim Friede, Frederike Lentz, Nigel Stallard, Sarah Zohar, A dose finding design for seizure reduction in neonates, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12289, 68, 2, (427-444), (2018).
- Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, Jun Yin, gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12263, 68, 2, (289-308), (2018).
- Daniel G Muenz, Thomas M Braun, Jeremy MG Taylor, Modeling adverse event counts in phase I clinical trials of a cytotoxic agent, Clinical Trials, 10.1177/1740774518772309, 15, 4, (386-397), (2018).
- Elizabeth Garrett-Mayer, Nathaniel O’Connell, The Evolution of Phase I Trials, Past, Present, and Future, Novel Designs of Early Phase Trials for Cancer Therapeutics, 10.1016/B978-0-12-812512-0.00003-8, (17-32), (2018).
- Khanh Do, Chris H. Takimoto, Shivaani Kummar, Changing Landscape of Early Phase Clinical Trials, Novel Designs of Early Phase Trials for Cancer Therapeutics, 10.1016/B978-0-12-812512-0.00001-4, (1-6), (2018).
- Ruitao Lin, Bayesian optimal interval design with multiple toxicity constraints, Biometrics, 10.1111/biom.12912, 74, 4, (1320-1330), (2018).
- Niansheng Tang, Songjian Wang, Gen Ye, A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies, BMC Medical Research Methodology, 10.1186/s12874-018-0604-9, 18, 1, (2018).
- Cody Chiuzan, Elizabeth Garrett-Mayer, Michael I. Nishimura, An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1462727, 10, 3, (185-195), (2018).
- Shing M Lee, Moreno Ursino, Ying Kuen Cheung, Sarah Zohar, Dose-finding designs for cumulative toxicities using multiple constraints, Biostatistics, 10.1093/biostatistics/kxx059, 20, 1, (17-29), (2017).
- Cody Chiuzan, Jonathan Shtaynberger, Gulam A. Manji, Jimmy K. Duong, Gary K. Schwartz, Anastasia Ivanova, Shing M. Lee, Dose-finding designs for trials of molecularly targeted agents and immunotherapies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1289952, 27, 3, (477-494), (2017).
- Thomas A. Murray, Ranking ultimate teams using a Bayesian score-augmented win-loss model, Journal of Quantitative Analysis in Sports, 10.1515/jqas-2016-0097, 13, 2, (2017).
- Zhengjia Chen, Zheng Li, Run Zhuang, Ying Yuan, Michael Kutner, Taofeek Owonikoko, Walter J. Curran, Jeanne Kowalski, Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile, PLOS ONE, 10.1371/journal.pone.0170187, 12, 1, (e0170187), (2017).
- Ruitao Lin, Guosheng Yin, Nonparametric overdose control with late-onset toxicity in phase I clinical trials, Biostatistics, 10.1093/biostatistics/kxw038, 18, 1, (180-194), (2016).
- Ruitao Lin, Guosheng Yin, Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials, Advanced Statistical Methods in Data Science, 10.1007/978-981-10-2594-5_4, (55-74), (2016).
- Ying Kuen Cheung, A Review of Dose Finding Methods and Theory, Communications for Statistical Applications and Methods, 10.5351/CSAM.2015.22.5.401, 22, 5, (401-413), (2015).
- Bin Cheng, Shing M. Lee, On the consistency of the continual reassessment method with multiple toxicity constraints, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2015.03.001, 164, (1-9), (2015).
- William W. Tseng, Shouhao Zhou, Christina A. To, Peter F. Thall, Alexander J. Lazar, Raphael E. Pollock, Patrick P. Lin, Janice N. Cormier, Valerae O. Lewis, Barry W. Feig, Kelly K. Hunt, Matthew T. Ballo, Shreyaskumar Patel, Peter W. T. Pisters, Phase 1 adaptive dose‐finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high‐risk extremity and trunk soft tissue sarcoma, Cancer, 10.1002/cncr.29544, 121, 20, (3659-3667), (2015).
- Ick Hoon Jin, Lin Huo, Guosheng Yin, Ying Yuan, Phase I trial design for drug combinations with Bayesian model averaging, Pharmaceutical Statistics, 10.1002/pst.1668, 14, 2, (108-119), (2015).
- Xavier Paoletti, Adélaïde Doussau, Monia Ezzalfani, Elisa Rizzo, Rodolphe Thiébaut, Dose finding with longitudinal data: simpler models, richer outcomes, Statistics in Medicine, 10.1002/sim.6552, 34, 22, (2983-2998), (2015).
- Kit Man Wong, Anna Capasso, S. Gail Eckhardt, The Changing Landscape of Phase I Trials in Oncology, American Society of Clinical Oncology Educational Book, 10.14694/EdBook_AM.2015.35.3, 35, (3-8), (2015).
- Kit Man Wong, Anna Capasso, S. Gail Eckhardt, The changing landscape of phase I trials in oncology, Nature Reviews Clinical Oncology, 10.1038/nrclinonc.2015.194, 13, 2, (106-117), (2015).
- Nolan A. Wages, Christopher Tait, Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920873, 25, 5, (903-920), (2014).
- Cody Chiuzan, Elizabeth Garrett-Mayer, Sharon D Yeatts, A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774514555585, 12, 1, (24-33), (2014).
- Yunfei Wang, Anastasia Ivanova, Dose finding with continuous outcome in phase I oncology trials, Pharmaceutical Statistics, 10.1002/pst.1662, 14, 2, (102-107), (2014).
- Zhengjia Chen, Ye Cui, Taofeek K. Owonikoko, Zhibo Wang, Zheng Li, Ruiyan Luo, Michael Kutner, Fadlo R. Khuri, Jeanne Kowalski, Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2014.02.004, 37, 2, (322-332), (2014).
- Sylvie Chevret, Phase I Trials including Phase I Cancer Trials, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Sylvie Chevret, Phase I Trials, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596005, (682-691), (2014).
- Mourad Tighiouart, Steven Piantadosi, André Rogatko, Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control, Statistics in Medicine, 10.1002/sim.6201, 33, 22, (3815-3829), (2014).
- Ying Kuen Cheung, Simple benchmark for complex dose finding studies, Biometrics, 10.1111/biom.12158, 70, 2, (389-397), (2014).
- Haitao Pan, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, Jielai Xia, The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach, PLoS ONE, 10.1371/journal.pone.0098147, 9, 5, (e98147), (2014).
- Darsy Darssan, Mery H. Thompson, Anthony N. Pettitt, Incorporating adverse event relatedness into dose‐finding clinical trial designs, Statistics in Medicine, 10.1002/sim.6011, 33, 7, (1146-1161), (2013).
- Anastasia Ivanova, Gary L. Rosner, Olga Marchenko, Tom Parke, Inna Perevozskaya, Yanping Wang, Advances in Statistical Approaches to Oncology Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479013501309, 48, 1, (81-89), (2013).
- Zhengjia Chen, Zhibo Wang, Haibin Wang, Taofeek K Owonikoko, Jeanne Kowalski, Fadlo R Khuri, Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials, The Open Medical Informatics Journal, 10.2174/1874431101307010008, 7, 1, (8-17), (2013).
- Takashi Asakawa, Chikuma Hamada, A pragmatic dose‐finding approach using short‐term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials, Pharmaceutical Statistics, 10.1002/pst.1590, 12, 5, (315-327), (2013).
- Monia Ezzalfani, Sarah Zohar, Rui Qin, Sumithra J. Mandrekar, Marie‐Cécile Le Deley, Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities, Statistics in Medicine, 10.1002/sim.5737, 32, 16, (2728-2746), (2013).
- Guosheng Yin, Shurong Zheng, Jiajing Xu, Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2013.789892, 23, 4, (856-870), (2013).
- Jennifer A. Harrington, Graham M. Wheeler, Michael J. Sweeting, Adrian P. Mander, Duncan I. Jodrell, Adaptive designs for dual-agent phase I dose-escalation studies, Nature Reviews Clinical Oncology, 10.1038/nrclinonc.2013.35, 10, 5, (277-288), (2013).
- Mourad Tighiouart, Galen Cook-Wiens, André Rogatko, Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials, Journal of Probability and Statistics, 10.1155/2012/317634, 2012, (1-18), (2012).
- Emily M Van Meter, Elizabeth Garrett-Mayer, Dipankar Bandyopadhyay, Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774512443593, 9, 3, (303-313), (2012).
- Takashi Daimon, The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs., Japanese Journal of Biometrics, 10.5691/jjb.33.31, 33, 1, (31-76), (2012).
- Zhengjia Chen, Mourad Tighiouart, Jeanne Kowalski, Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2012.04.007, 33, 5, (949-958), (2012).
- Ying Kuen Cheung, Designs for Phase I Trials, Designs for Clinical Trials, 10.1007/978-1-4614-0140-7, (1-27), (2012).
- Guosheng Yin, References, Clinical Trial Design, undefined, (311-327), (2012).
- Peter F. Thall, Hoang Q. Nguyen, Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2012.676586, 22, 4, (785-801), (2012).
- Sarah Zohar, Matthieu Resche-Rigon, Sylvie Chevret, Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511411593, 10, 3, (414-421), (2011).
- S. M. Lee, D. L. Hershman, P. Martin, J. P. Leonard, Y. K. Cheung, Toxicity burden score: a novel approach to summarize multiple toxic effects, Annals of Oncology, 10.1093/annonc/mdr146, 23, 2, (537-541), (2011).
- Alexia Iasonos, Sarah Zohar, John O'Quigley, Incorporating lower grade toxicity information into dose finding designs, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511410732, 8, 4, (370-379), (2011).
- Mark Chang, Mark Chang, Bayesian Methods and Applications, Modern Issues and Methods in Biostatistics, 10.1007/978-1-4419-9842-2_10, (261-289), (2011).
- Emily M. Van Meter, Elizabeth Garrett‐Mayer, Dipankar Bandyopadhyay, Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading, Statistics in Medicine, 10.1002/sim.4069, 30, 17, (2070-2080), (2011).
- S. M. Lee, B. Cheng, Y. K. Cheung, Continual reassessment method with multiple toxicity constraints, Biostatistics, 10.1093/biostatistics/kxq062, 12, 2, (386-398), (2010).
- undefined Yuan Ji, undefined Ping Liu, undefined Yisheng Li, B. Nebiyou Bekele, A modified toxicity probability interval method for dose-finding trials, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774510382799, 7, 6, (653-663), (2010).
- Guosheng Yin, Ying Yuan, Bayesian Approach for Adaptive Design, Handbook of Adaptive Designs in Pharmaceutical and Clinical Development, 10.1201/b10279, (3-1-3-19), (2010).
- Zhengjia Chen, Mark D. Krailo, Stanley P. Azen, Mourad Tighiouart, A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2010.05.010, 31, 5, (473-482), (2010).
- B. Nebiyou Bekele, Advances in Oncology Clinical Research: Statistical and Study Design Methodologies, Lung Cancer, 10.1007/978-1-60761-524-8, (467-481), (2010).
- B. Nebiyou Bekele, Yisheng Li, Yuan Ji, Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score, Biometrics, 10.1111/j.1541-0420.2009.01297.x, 66, 2, (541-548), (2009).
- Nadine Houede, Peter F. Thall, Hoang Nguyen, Xavier Paoletti, Andrew Kramar, Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials, Biometrics, 10.1111/j.1541-0420.2009.01302.x, 66, 2, (532-540), (2009).
- Sarah Zohar, John O'Quigley, Sensitivity of dose-finding studies to observation errors, Contemporary Clinical Trials, 10.1016/j.cct.2009.06.008, 30, 6, (523-530), (2009).
- Guosheng Yin, Ying Yuan, Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials, Journal of the American Statistical Association, 10.1198/jasa.2009.ap08425, 104, 487, (954-968), (2009).
- Richard F. Potthoff, Stephen L. George, Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations, Statistics in Biopharmaceutical Research, 10.1198/sbr.2009.0014, 1, 3, (213-228), (2009).
- Anastasia Ivanova, Michael Murphy, An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations, Journal of Biopharmaceutical Statistics, 10.1080/10543400802609805, 19, 2, (247-255), (2009).
- Anastasia Ivanova, Se Hee Kim, Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach, Biometrics, 10.1111/j.1541-0420.2008.01045.x, 65, 1, (307-315), (2008).
- Guosheng Yin, Ying Yuan, A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents, Biometrics, 10.1111/j.1541-0420.2008.01119.x, 65, 3, (866-875), (2008).
- Jeffrey S. Barrett, Bhuvana Jayaraman, Dimple Patel, Jeffrey M. Skolnik, A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2007.12.008, 90, 3, (240-250), (2008).
- Ying Yuan, Guosheng Yin, Sequential continual reassessment method for two‐dimensional dose finding, Statistics in Medicine, 10.1002/sim.3372, 27, 27, (5664-5678), (2008).
- Sylvie Chevret, Phase I Trials, Wiley Encyclopedia of Clinical Trials, 10.1002/9780471462422, (1-8), (2007).




